Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented research at the AD/PD 2023 conference showcasing a human model using iPSC-derived excitatory neurons to study drug binding to amyloid beta oligomers linked to Alzheimer’s disease (AD). Key findings indicate oligomer size affects neuronal binding, underscoring the significance of oligomer preparation and antibody selection in assays. This research supports Acumen's clinical development of ACU193, a monoclonal antibody targeting toxic globular sAβOs, with patient enrollment completed for its Phase 1 INTERCEPT-AD trial. The poster presentation is scheduled for March 28 and will be accessible throughout the conference.